SCHEMBL21201012

SCHEMBL21201012

CC(=O)c1cc(C(=O)Nc2cccc(C3(Cc4nncn4C)COC3)c2)nc(C2CC2)n1

nearest known ligand 0.88

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ CBLB Q13191 20/20 0.88

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29867306 1.00 CBLB (0.88) CBLB
SCHEMBL29866624 0.94 CBLB (1.00) CBLB
SCHEMBL21200497 0.94 CBLB (1.00) CBLB
SCHEMBL21201078 0.93 CBLB (0.87) CBLB
SCHEMBL29866819 0.93 CBLB (0.87) CBLB
SCHEMBL21200655 0.91 CBLB (0.83) CBLB
SCHEMBL29867714 0.91 CBLB (0.83) CBLB
SCHEMBL27272016 0.91 CBLB (0.83) CBLB
SCHEMBL21201300 0.91 CBLB (0.94) CBLB
SCHEMBL29866792 0.91 CBLB (0.94) CBLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3743063-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF Nurix Therapeutics, Inc. (US) 2020-12-02 — — EP disclosed
WO-2019148005-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF NURIX THERAPEUTICS, INC. (US) 2019-08-01 — — WO disclosed
Send feedback